EUCTR2012-002620-32-GB进行中（未招募）不适用
A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line treatment of Diffuse Large B-cell lymphoma (DLBCL) - LEGEND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologically proven CD20+ Diffuse Large B-Cell Lymphoma (DLBCL)
- •2.Availability of a tumour block containing adequate histological material for central pathology review and establishment of morphological and ontogenic subtype. Surgically acquired tissue samples are preferred but if core biopsy is the only suitable means by which to acquire a tissue sample then it is suggested than at least 2 cores are taken so that one can be embedded and sent for central review and one retained locally.
- •3.Relapsed after or refractory to one prior line of chemotherapy for DLBCL containing both rituximab and an anthracycline (eg R-CHOP)
- •o‘Relapsed’ is defined as investigator assessed progression after first line treatment
- •o‘Refractory’ is defined as patients who progressed during or who did not achieve complete remission with first line treatment (which should include radiotherapy if the patient had localised refractory disease)
- •4.Eligible for combination chemotherapy regimen
- •5.Patient is =18 years of age on the day of signing informed consent.
- •6.ECOG performance status 0, 1 or 2.
- •7.Baseline PET/CT scans must demonstrate FDG avid disease compatible with CT defined anatomical tumour sites.
- •8.Adequate bone marrow function: absolute neutrophil count (ANC) =1.0x109/l; white blood cell count = 3x109/l; platelets = 100x109/l; haemoglobin (Hb) = 9g/dl (can be post-transfusion), unless deemed disease related
- •9.Adequate renal function: calculated creatinine clearance =40ml/minute.
- •10.Adequate liver function: serum bilirubin =1.5x ULN; ALT/AST =2.5x ULN; ALP =3x ULN (in the absence of liver metastases). If liver metastases are present, ALT, AST or ALP =5x ULN are permitted. Isolated hyperbilirubinaemia due to Gilbert’s disease is acceptable
- •11.Female patient of childbearing potential (FCBP) must have two negative serum ß-hCG pregnancy tests at baseline.
- •12.FCBP agreeable to practice sexual abstinence or use two forms of contraception from 28 days prior to the period of study treatment and for 12 months after the last dose of study drugs.
- •13.Male patients agreeable to practice sexual abstinence use condoms from 28 days prior to the period of study treatment and for 12 months after the last dose of study drugs.
- •14.Recovery from toxicity from previous anti-cancer treatment to = grade 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 56
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Documented or symptomatic central nervous system involvement or leptomeningeal disease.
- •2.Any other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial, including active or chronic infection, poorly controlled diabetes mellitus, congestive cardiac failure, cardiac arrhythmia, coronary artery disease, cerebrovascular disease, or severe pulmonary disease
- •3.Any other malignancies diagnosed or treated within the last 5 years (other than curatively treated basal cell or squamous cell carcinoma of the skin and/or in situ carcinoma of the cervix or breast).
- •4.Received drug treatment for cancer within 21 days of commencing study treatment.
- •5.Received previous lenalidomide
- •6.Evidence of human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or active hepatitis B infection.
- •7.Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing study treatment.
- •8.Hypersensitivity or contraindication to any of the study drugs as stated in the SmPCs for each of the study drugs.
- •9.Prior stem cell or solid organ transplant
- •10.Treatment with an investigational product within 30 days prior to enrolment
- •11.Not able to provide fully informed consent because of intellectual impairment or psychiatric disorder
- •12.Patient unwilling or not able to adhere to the Lenalidomide Pregnancy Prevention Programme (Appendix I)
研究者
相似试验
进行中（未招募）
1 期
Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide inSecond Line Multiple Myeloma (MM)Multiple myelomaMedDRA version: 16.1Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-021857-38-SEKarolinska University Hospital60
进行中（未招募）
1 期
A study of the efficacy and safety of the drug lenalidomide used alone compared with lenalidomide together with a low dose of the drug dexamethasone in patients with the blood cell tumor disease multiple myeloma (MM) who have failed on the first therapyMultiple myelomaMedDRA version: 17.0Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-021857-38-DKKarolinska University Hospital/Huddinge60
进行中（未招募）
不适用
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-camCLL patientsMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-001823-71-ITAssociazione Malattie Sangue ONLUS
进行中（未招募）
不适用
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
不适用
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH